Wenxue Ma, MD, PhD, is a distinguished specialist in Immuno-Oncology and serves as a physician-scientist at the University of California, San Diego. He earned his MD and PhD from Zhejiang University, China, with research focusing on Cancer Immunology, Cancer Immunotherapy, and Cancer Stem Cells. In 2013, he discovered cancer stem cell markers in T-cell acute lymphoblastic leukemia (T-ALL), leading to the patents WO2013044164 and WO2022165398 for cancer treatment. In 2020, he identified tumor antigen sequences with enhanced immunogenicity over the natural survivin peptide sequence. He is a member of prominent professional organizations, including SITC, ASCO, AACR, ISSCR, ASH, JCA, and the RSM. He authored or co-authored approximately 116 publications in Cancer Immunology and Oncology, with over 3466 citations. In addition to his research, he serves as an Associate Editor for Frontiers in Immunology and Frontiers in Oncology, and as an Editorial Board Member for Discover Oncology, Oncology Research, World Journal of Clinical Oncology, and Oncology Advances. Since 2006, he has reviewed for 60 medical-related journals. Since January 2023, he has also served as a Grant Evaluation Reviewer for the European Science Foundation (ESF) and the Research Foundation Flanders (FWO) for research communities.